Metropolis Healthcare Limited launches the ‘NextGen HLA’ High Resolution Typing Test

Powered by the complex molecular technology ‘Next Generation Sequencing (NGS)’. Metropolis’ NextGen HLA Typing is a high-resolution molecular test, which is performed for Hematopoietic Stem Cell Transplant (HSCT) & Solid organ transplantation. This test aids in the identification of a suitable donor for bone marrow, cord blood, or organ transplant by analysing the Human Leukocyte Antigen (HLA) genes that a person has inherited from the parents.

HLA encodes proteins found on the outer surface of cells that is part of our body’s immune system. The immune system uses HLAs to differentiate self-cells & non-self cells. HLA system is activated when the body encounters something foreign, such as transplants, and attempts to reject it leading to graft failure. Prior knowledge of HLA allelic genetic variants is clinically important for matching donor and recipient for Hematopoietic & organ transplantation. HLA allelic information can also be used to predict immune responses to a variety of infectious diseases, genetic & autoimmune disorders.The HLA genes determine a person’s unique HLA Type, which is critical for transplant success. The NGS-based HLA Typing test, widely regarded as the gold standard approach, eliminates ambiguity in HLA Typing and provides the most accurate characterization of Alleles, making it one of the most advanced and reliable tests available in the market.

Metropolis’ NextGen HLA Typing test will greatly benefit doctors, patients, and transplant physicians, as it ensures a higher percentage of HLA matches between donor and recipient, thus increasing the chances of successful transplant outcomes. This will reduce the risk of immune complications such as graft rejection, Graft vs Host Disease (GVHD) and improve the survival rate of patients undergoing HSCT.Commenting on the launch of the test, Dr Sushil Shah, Chairman, Metropolis Healthcare said: “Metropolis Healthcare has established a centre of excellence for all transplant-related diagnostic services, including the most comprehensive array of diagnostic tools, reports with more accurate interpretation, expert laboratory professionals, and subject matter specialists, making Metropolis a one-stop solution for all the transplant-related diagnostic needs. We believe that this test will help doctors find the right donors for their patients, resulting in successful transplants and higher survival rates.”

Dr Kirti Chadha, Chief Scientific Officer, Metropolis Healthcare Limited said: “The human leukocyte antigen (HLA) genes are the most diverse loci in the human genome. This allelic diversity constitutes one of the major genetic differences between individuals & different ethnic populations. Therefore, the HLA genes are clinically relevant as key determinants of compatibility in organ and bone marrow transplantation. This poses challenges to develop molecular approaches to genotype HLA alleles. With the validation of NGS for HLA genotyping, we now have the ability to better define genes, identifying polymorphisms, resolving all ambiguities that have significant clinical impact.”Established in 1981, Metropolis Healthcare Limited is a leading diagnostics company in India with a widespread presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company is empowered with a robust network of over 172 labs, 3379 collection centres and 10000+ touch points. Metropolis’ commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98 per cent over the past decade, which places it amongst the top 1 per cent laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or follow us on Twitter, Facebook, or LinkedIn

Media Contact:

Metropolis Healthcare Limited

Jeyasingh BalakrishnanHead – Corporate Communications

Mobile: +91 9833836185Email: Jeyasingh.b@metropolisindia.com

This story has been provided by SRV. ANI will not be responsible in any way for the content of this article.